VYGR - Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting | Benzinga
LEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a broad set of data related to its TRACER™ capsid discovery platform and TRACER-driven gene therapy programs across 12 oral and poster presentations at the upcoming American Society of Gene & Cell Therapy's (ASGCT) 27th annual meeting taking place in Baltimore, May 7-11. The findings span the cross-species and receptor-driven translatability, manufacturability, and overall performance of Voyager's novel IV-delivered CNS capsids, which are enabling multiple gene therapies to advance towards clinical trials next year.
"Voyager's novel TRACER-derived capsids underlie 13 partnered programs and three wholly-owned programs to enable IV-delivery of gene therapies for diseases of the central nervous system. Three of those programs now have development candidates selected, and we see the potential for them to enter clinical trials next year," said Todd Carter, Ph.D., Chief Scientific Officer of Voyager Therapeutics. "At ASGCT, we will highlight data on the second-generation capsids that have enabled this progress, as well as preclinical data from our wholly-owned Alzheimer's disease and ALS programs, and multiple studies of cross-species and receptor-based data that increase our confidence in the potential for these capsids to work in humans."
Second-Generation Capsids
- Oral Presentation: Continued directed evolution of VCAP-101 and VCAP-102 identifies second generation capsids with increased brain tropism in non-human primates and mice (#119). Tyler Moyer, Ph.D., Senior Scientist I, Novel Capsid Discovery. Wednesday, May 8, 2024, 4:30 p.m. – 4:45 p.m. ET
Advancements in Wholly-Owned CNS Gene Therapy Programs
- Intravenous administration of BBB-penetrant, MAPT-Silencing, AAV gene therapy provides broad and robust CNS Tau lowering in tauopathy mouse models (#1602). Hechen Bao, Ph.D., Scientist I, and Shiron Lee, M.S., Senior Research Associate I, Neuroscience. Friday, May 10, 2024, 12:00 p.m. ET
- Intravenous delivery of AAV gene therapy for the treatment of SOD1-ALS provides broad SOD1 lowering in NHP (#1647). Michael Grannan, Ph.D., Associate Director, Neuroscience. Friday, May 10, 2024, 12:00 p.m. ET
Mechanism of Action and Cross-Species Translation
- Identification and characterization of a highly conserved cell surface receptor utilized by engineered BBB-penetrant AAV capsids with enhanced brain tropism in non-human primates and mice (#975). Brett Hoffman, Ph.D., Senior Scientist II, Novel Capsid Discovery. Thursday, May 9, 2024, 12:00 p.m. ET
- Establishment of a predictive transcytosis model to recapitulate capsid-receptor interaction and phenotype of BBB-penetrant AAV variants (#976). Ishan Shah, Ph.D., Senior Scientist I, Vector Genome. Thursday, May 9, 2024, 12:00 p.m. ET
- Evaluation ...